Exagen (XGN) Q2 FY26 earnings call

Exagen delivered an outstanding quarter, achieving record revenue, AVISE test volume, and trailing 12-month ASP, while significantly narrowing its adjusted EBITDA loss to near breakeven. This performance reflects disciplined execution of its strategy focused on product adoption, ASP expansion through revenue cycle management, and continuous innovation. The company is positioned for sustained profitability, with a new myositis product launch anticipated in early 2027 and ongoing investments in AI-powered commercial infrastructure.